Risks of liver, cardiovascular or lung issues stemming from Sanofi's Multaq irregular heart beat drug mean its use should be restricted, Europe's drug regulator said on Thursday following a safety review. The decision could raise further pressure on Sanofi to speed up the replenishment of a drug pipeline which has been drastically diminished after a top-to-bottom review. Following a monthly meeting, the regulator's Committee on Medicinal Products for Human Use (CHMP) in London recommended the drug should only be prescribed "after alternative treatment options have been considered".
